Background: Fructose induces nonalcoholic fatty liver disease (NAFLD). Citrulline (Cit) may exert a beneficial effect on
Introduction
Nonalcoholic fatty liver disease (NAFLD) 7 , which is initiated by pathologic hepatic lipid accumulation (1) , is among the most common causes of chronic liver disease in many countries, and its prevalence is increasing (1) . One striking feature of NAFLD is its strong association with an unhealthy dietary pattern (2) , and fructose may be one of the key factors in its development (2) .
Indeed, the consumption of fructose-rich food (such as highfructose corn syrup-containing staples or sugar-sweetened beverages) has detrimental effects in animals (3) and humans (4) . Fructose is shown to induce de novo lipogenesis (DNL) in the liver by activating key lipogenic enzymes via sterol regulatory elementbinding protein-1c (SREBP1c) (5, 6) or carbohydrate-responsive element-binding protein (ChREBP) (6) , and to promote hepatic oxidative stress (7) . Chronic intake of fructose also leads to insulin resistance (7) . In addition, lipogenesis induced by a high-fructose consumption leads to alterations in interorgan lipid fluxes and fat deposition in adipose tissue and muscles (8) .
It is suggested that dietary amino acid (AA) or protein supplementation may improve fructose-induced steatosis (9-11) via their effects on lipid metabolism, insulin sensitivity, and glucose tolerance. Theytaz et al. (9) found an increase in VLDL-TG release by the liver with an essential AA-enriched diet, and Bortolotti et al. (11) showed that a protein-enriched diet also reduced fructoseinduced lipid accumulation in the liver through increased energy expenditure. These beneficial effects of AAs or proteins may arise through lipid oxidation, decreased DNL, and modulation of genes involved in lipid metabolism. In this respect, citrulline (Cit) could also be effective. Cit is the precursor for the renal synthesis of Arg, an AA known to improve insulin sensitivity (12) , and several studies have shown that it can improve lipid metabolism. Indeed, Cit has a beneficial effect on plasma TGs, as shown by El-Bassossy et al. (13) in a model of hypertension. Moinard et al. (14) showed that Cit decreases fat deposition, likely through activation of lipolysis and b-oxidation in adipose tissue, leading to decreased nonesterified free FA (NEFA) release (15) . Finally, Cit is involved in the regulation of protein and energy metabolism (16) because it activates muscle protein synthesis (17) and improves insulin sensitivity. Moreover, Cit also displays antioxidative properties, as previously shown by our group in a model of in vivo ischemia-reperfusion of the liver (18) . Therefore, Cit may be able to restore hepatic energy metabolism, which plays a major role in the development of NAFLD. We previously showed in shortterm experiments (4-wk fructose feeding) that Cit was associated with decreased fat accumulation and normalized plasma TGs (19) . However, our results did not enable us to discriminate between a nonspecific effect of increased AA supply and a specific effect of Cit.
Our working hypothesis was that nonessential AA (NEAA) and Cit supplementations might both be able to limit the development of fructose-induced NAFLD. We speculated that this may occur by both a global effect of nitrogen supply and a specific effect of Cit on lipid metabolism.
Thus, the aim of this study was to assess the effects of oral NEAA or Cit administration on liver function in a rat model of NAFLD induced by 8-wk fructose feeding and to investigate the metabolic pathways involved.
Methods
Animals. Animal care and experimentation complied with both French and European Community regulations for animal care and experimentation. All procedures were conducted in accordance with the animal care guidelines of the ''Comité Régional dÕEthique pour lÕexpérimentation animale dÕIle-de-France,'' which also approved the study protocol (registration number 00737.02).
Male Sprague-Dawley rats weighing 190-220 g (Charles River) were individually housed for 1 wk in temperature-controlled rooms on a 12-h light/dark cycle before the experiments. The rats consumed water and standard rodent unpurified diet ad libitum (UAR A04; SAFE). For the feeding experiments, the animals received either standard rodent unpurified diet (SAFE) or a 60% fructose-enriched diet (U8960; SAFE).
Experimental design. Twenty-two rats were randomly assigned to 4 groups (n = 4-6 rats per group) and received for 8 wk either the control diet supplemented with NEAAs (alanine, glycine, proline, aspartate, histidine, and serine) (CNEAA group) or a 60% fructose-enriched diet, either alone (F group) or with NEAAs (FNEAA group), or Cit (FCit group) (composition of the diets are given in Supplemental Tables 1-3 ). Given that in previous experiments from our team control diets supplemented with NEAAs or Cit had metabolic and nutritional effects similar to the control diet alone (17, 19) , we opted to include only the CNEAA group to limit the number of animals used. In the FCit group, Cit was given at 1 g Á kg 21 Á d
21
. This dose of Cit was chosen on the basis of our previous studies (20, 21) . The NEAA supplement contained isomolar amounts of the 6 AAs and was isonitrogenous to Cit. The rats consumed diet and water ad libitum.
During the 8-wk feeding period, food intake and body weight gain were monitored weekly.
At the end of the feeding period, the rats were deprived of food and anesthetized by isoflurane inhalation. Arterial blood was collected from the abdominal aorta into heparin-containing tubes. The animals were then killed by exsanguination. Liver samples were taken and frozen in liquid nitrogen for the determination of hepatic TG (HTG) content and kept at 280°C until analysis. Body composition and in particular localization and size of fat depots were determined by dissection and weighing.
Blood samples were immediately centrifuged (10 min, 2500 3 g, 4°C). An aliquot of plasma was immediately deproteinized with a 30% (wt:vol) sulfosalicylic acid solution for plasma AA analysis. Another aliquot of plasma was frozen at 280°C until analysis of metabolic status.
Metabolic assessment. Plasma AAs were separated and quantified by ion exchange chromatography with postcolumn ninhydrin detection with the use of a JLC-500/VAminoTac analyzer (Jeol Ltd.). Plasma liver enzyme activities [alanine aminotransferase (ALT), aspartate aminotransferase, alkaline phosphatase], bilirubin, total cholesterol, TGs, glucose, and uric acid were determined with standard techniques on a multiparameter analyzer (Cobas C 6000; Roche).
Plasma insulin was measured by ELISAwith the use of a commercial kit (ultrasensitive rat insulin ELISA; Mercodia) according to the manufacturerÕs protocol. Insulin sensitivity was evaluated with the HOMA-IR [fasted insulin (in mU/L) 3 fasted glucose (in mM)/22.5].
Plasma NEFAs and creatinine were assessed with commercial kits (Free Fatty Acid Quantification Kit, and Creatinine Assay Kit, respectively; Abcam) according to the manufacturerÕs protocols.
Determination of HTG content. Frozen liver samples were homogenized in ice-cold 23 PBS. Tissue lipids were extracted with methanol: chloroform (1:2), dried, and resuspended in 5% fat-free BSA in sterile water. HTG was assessed with a commercial kit (TG PAP 150; Biomérieux).
RNA isolation and real-time PCR. Total RNA from liver samples was prepared with TRIzol reagent (Invitrogen), and cDNA was synthesized with the QuantiTect Reverse Transcription kit (Qiagen). Real-time PCR was performed with the QuantiTect SYBER Green PCR kit (Qiagen) according to the manufacturerÕs instructions. To control for variations in the reactions, all PCR data were normalized against b-actin expression. PCR primers for acetyl-CoA carboxylase, Chrebp, carnitine palmitoyltransferase 1a (Cpt1a), diglyceride acyltransferase, Il6, liver-type FAbinding protein (lFabp), microsomal TG transfer protein (Mtp), peroxisome proliferator-activated receptor a (Ppara), Srebp1c, and toll-like receptor 4 (Tlr4) genes are described in Supplemental Table 4 .
The comparative CT method was used to determine the amount of target gene, and the results were normalized to an endogenous reference gene (b-actin).
Data analysis. Results are expressed as means 6 SEMs. Statistical analysis was performed with Prism 6.0 (GraphPad Inc.). Homogeneity of variance of data were assessed with a Bartlett test. Differences between groups were analyzed with ANOVA, followed by a FisherÕs protected lease significant difference test. In case of heterogeneity of variance a KruskallWallis test, followed by a Dunn test, was performed. For daily food intake and body weight, repeated-measure ANOVA was used, and differences were analyzed with a Bonferroni test. For all the tests, P < 0.05 was considered significant.
Results
Effect of diet on food intake, body weight, and adiposity. After 8 wk, body weight was significantly lower in the F group than in the other 3 groups (P < 0.05) despite similar food intake; this was associated with significant differences in body composition, fructose diet resulting in higher visceral fat mass (P < 0.05), and lower lean mass (P < 0.05) than in the other 3 groups ( Table 1) . No significant between-group differences were found in subcutaneous fat mass ( Table 1) .
Effect of diet on metabolic variables. The F group displayed higher plasma TGs, glucose, insulin, and insulin-resistance than the other 3 groups (P < 0.05) ( Table 2 ). Plasma cholesterol, NEFA, and uric acid did not differ among the groups (Table 2) .
Plasma creatinine and urea were greater in the F group than in the other 3 groups (P < 0.05). In parallel, the fructose diet resulted in altered plasma AA profiles ( Table 3) . Compared with the CNEAA group, the F group showed significantly higher plasma concentrations of 2 sulfur AAs (methionine and taurine), gluconeogenic AAs (threonine, asparagine, alanine, proline, and glycine), and tyrosine (P < 0.05) and tended to show higher phenylalanine (P = 0.08). In the FNEAA and FCit groups, concentrations of all AAs (except glycine) were significantly lower than in the F group (P < 0.05) and similar to the CNEAA group.
Fructose induced a 10% decrease in plasma Arg, but this did not reach statistical significance (P = 0.07), compared with the CNEAA group, and this was corrected only in the FCit group (P = 0.09 vs. F group). Plasma Cit was higher in the F group than in the other 3 groups (P < 0.05). The ratio of Arg to ornithine + Cit, which can be considered as a marker of global Arg metabolism (22) , tended to be lower in the F group than in the CNEAA group (P = 0.08) ( Figure 1A ). In the FCit group, but not in the FNEAA group, this ratio tended to be higher than in the F group (P = 0.09). Plasma Lys was significantly higher in the F group than in the other 3 groups (P < 0.05). Arg availability, defined as Arg-to-Lys ratio (12) , was lower in the F group than in the other 3 groups (P < 0.05) ( Figure 1B ). Although both NEAA and Cit supplementation resulted in a significantly higher Arg-to-Lys ratio than in the F group, it was significantly higher in the FCit group than in the FNEAA group. Branched-chain AA concentrations were similar in all 4 groups.
Effect of NEAAs or Cit on hepatic steatosis. In the F group, chronic consumption of the fructose diet produced a significantly higher liver-to-body weight ratio and higher HTG than in the CNEAA group (Table 4) . In parallel, plasma concentrations of ALT but not aspartate aminotransferase were significantly higher in the F group than in the CNEAA group (Table 4 ). In the FNEAA and FCit groups, all these variables were significantly higher than in the F group and were similar to the CNEAA group (Table 4) .
Effect of NEAAs or Cit on genes involved in liver lipid accumulation. Expression of lFabp tended to be higher in the F group than in the CNEAA group (P = 0.09) (Figure 2A) . Expression of FA synthase gene (Fas; Figure 2B ), a key enzyme of DNL, was significantly higher in the F group than in the other 3 groups. Interestingly, Fas expression in the FCit group was significantly lower than in the FNEAA group and was similar to the CNEAA group. No significant differences were observed in Dgat ( Figure 2C ) and acetyl-CoA carboxylase ( Figure 2D ) gene expression among the 4 groups. Expression of Cpt1a ( Figure 2E ) and Mtp ( Figure 2F ) was lower (P < 0.05) in the F group than in the other 3 groups. In the F group the expression of transcription factors Srebp1c ( Figure 2G ) and Chrebp ( Figure 2H ) was significantly higher and that of Ppara ( Figure 2I ) was lower than in the other 3 groups. Srebp1c expression in the FNEAA group and Chrebp expression in the FNEAA and FCit groups were significantly higher than in the CNEAA group.
Effect of NEAAs or Cit on liver inflammation. In the F group, the animals displayed hepatic inflammation characterized by higher Tlr4 ( Figure 2J ) and Il6 ( Figure 2K ) expression (P < 0.05) compared with the other 3 groups. 
Discussion
Chronic fructose intake may be a critical factor in the development of NAFLD (3, 23) , and AA supplementation may be protective (9, 24) . Here, we show that NEAAs or Cit prevents the development of fructose-induced NAFLD, presumably via different pathways, because, in addition to their effects on lipid metabolism, only Cit improves Arg metabolism, which is important in the long-term management of insulin-resistance. As expected, fructose increased liver weight through hepatic lipid accumulation, presumably via 1) a 2-fold increase in lFabp expression, suggesting increased NEFA uptake; 2) a lower Cpt1a and Ppara expression, suggesting decreased b-oxidation; 3) induction of Chrebp, Srebp1c, and Fas expression, the main controlling factors of DNL; and 4) decreased expression of Mtp involved in VLDL production. Conversely, we showed beneficial effects of NEAAs and Cit on all these steps of hepatic fat deposition. At least 2 mechanisms may be involved in the effects of Cit and NEAAs: restored Ppara expression, as was already shown for Cit in adipose tissue (15) , enabling enhanced NEFA oxidation, and depressed DNL through decreased expression of Srebp1c and Chrebp and their target gene Fas. Interestingly, Cit had a more marked effect on Fas and Srebp1c mRNA expression than NEAAs. This may be related to the control of Srebp1c expression in part by the protein kinase B and mammalian target of rapamycin (mTOR) pathway (25) and the effect of Cit on this pathway (16) . It must be noted that the NEAA supplement is composed of 6 different AAs, so that none of them is supplied in an amount associated with a specific metabolic effect. Thus, NEAA effects may occur via signaling pathways sensitive to global AA availability such as general control nonderepressible 2 (GCN2) (26) . Finally, these effects of NEAAs or Cit on hepatic lipid metabolism were associated with decreased plasma TGs. Besides the improvement in hepatic metabolism, an increase in VLDL clearance may occur as a consequence of improved insulin sensitivity. Measurement of lipid fluxes would be necessary to elucidate the underlying process.
In addition to hepatic lipid accumulation, 8-wk fructose feeding also induced inflammation as shown by increased hepatic Il6 and Tlr4 gene expression, and this was prevented by NEAAs and Cit. As a consequence, liver function was impaired, as shown by the increase in plasma ALT activity, suggesting a progression from simple steatosis to steatohepatitis; this was prevented by Cit and NEAA supply, which for Cit is in line with its antiinflammatory properties (27) .
Fructose also produced an overall change in nutritional and metabolic status, with lower body weight and altered body composition, whereas food/energy intake was similar among groups. Fructose resulted in higher visceral fat mass, as shown by others (28) , but also lower lean body mass despite protein intake similar to controls. Although a possible increase in energy expenditure may contribute (29) , our data suggest a specific role of excess fructose on nitrogen homeostasis and muscle protein metabolism. Fructose feeding was associated with higher plasma amounts of several AAs, pointing to disturbances in AA metabolism and utilization for muscle protein synthesis. This is probably not related to impaired kidney function, because uric acid concentration was in the normal range, and AA profiles differed markedly from the pattern observed in progressive renal failure (30) . The higher plasma urea hints at increased hepatic AA utilization, in keeping with the increase in visceral mass and associated insulin resistance, leading to an induction of gluconeogenesis (31) . Moreover, dietary fructose may also stimulate gluconeogenesis (32, 33) . Thus, the increase in plasma AAs points to a defective muscle metabolism. Fructose-induced NAFLD may be responsible for a metabolic stress that affects muscle metabolism. Interestingly, Gatineau et al. (34) recently showed in aged rats that sucrose-fed animals lost significantly more lean body mass and retained more fat mass than starch-fed rats. In addition, they observed significantly lower meal-induced stimulation of muscle protein synthesis in sucrose-fed rats than in starch-fed rats (22%). Although the mechanisms remain to be elucidated, excess fructose consumption is known to be associated in the liver with 1) the production of substances such as methylglyoxal, an active glycating agent, leading to oxidative stress in muscle (35) , and 2) active DNL and endoplasmic reticulum stress (36) , leading to the production of hepatokines such as fetuin A (37), known to adversely affect muscle energy metabolism and insulin sensitivity (38) . Whatever the mechanism, our data suggest a diversion of nutrients for lipid storage at the expense of lean body mass accretion, which could explain these alterations in body composition.
Interestingly, body weight and composition were normalized by NEAA or Cit supply, and NEAAs and Cit restored interorgan AA fluxes and plasma urea and creatinine. These effects of AAs are probably due at least in part to their beneficial effect on hepatic steatosis. Moreover, AAs may have a beneficial direct effect on muscle protein metabolism (39) . In aged rats, Cit accelerates muscle protein synthesis (17) via mTOR/S6 kinase activation, whereas the same NEAAs proved ineffective. This suggests different mechanisms of action, and an effect of global AA availability on effectors such as GCN2 (40) may be proposed, but this needs further research. Alternatively, the beneficial effects of Cit and NEAAs may occur via the improvement in insulin sensitivity (29) .
From a metabolic standpoint, as expected (41), fructose induced hepatic and peripheral insulin resistance, as shown by the significant increase in HOMA-IR. Gaggini et al. (31) showed that hepatic insulin sensitivity decreased proportionally to both hepatic and visceral fat content, in keeping with clinical observations (42, 43) . Of note, the F group showed similar peripheral adipose tissue and higher visceral fat than the other groups but normal plasma NEFA amounts. Determination of portal plasma NEFAs would probably have better accounted for these modifications in visceral fat mass, as shown by Gaggini et al. (31) , owing to visceral fat lipolysis, which exposes the liver to even greater amounts of NEFA. Besides, Cit-induced improvement in insulin sensitivity may also occur through enhanced visceral adipose tissue lipolysis and fat oxidation (15) . Finally, Cit may act on insulin resistance via its effects on Arg availability and nitric oxide synthesis, which plays a key role in the regulation of energy FIGURE 2 Liver expression of genes involved in hepatic lipid accumulation and its regulation and in inflammation in rats fed a CNEAA, F, FCit, or FNEEA diet (1 g Á kg 21 Á d
21
) for 8 wk. The mRNA amounts for lFabp (A), Fas (B), Dgat (C), Acc (D), Cpt1a (E), Mtp (F), Srebp1c (G), Chrebp (H), Ppara (I), Il6 (J), and Tlr4 (K) were analyzed by real-time PCR. Values are means 6 SEMs, n = 6 or 4 (F). Labeled means without a common letter differ, P , 0.05. Acc, acetyl-CoA carboxylase gene; Chrebp, carbohydrate-responsive element-binding protein gene; Cit, citrulline; CNEAA, NEAA-supplemented control diet fed; Cpt1a, carnitine palmitoyltransferase 1a gene; Dgat, diglyceride acyltransferase 1 gene; F, 60% fructose-enriched diet fed; Fas, FA synthase gene; FCit, Cit-supplemented 60% fructose-enriched diet fed; FNEAA, NEAA-supplemented 60% fructose-enriched diet fed; lFabp, liver-type FA-binding protein gene; Mtp, microsomal TG transfer protein gene; NEAA, nonessential amino acid; Ppara, peroxisome proliferator-activated receptor a gene; Srebp1c, sterol regulatory element-binding protein-1c gene; Tlr4, toll-like receptor 4 gene. metabolism (44) . Fructose induced a decrease in plasma Arg, as observed in other models of insulin resistance in rats (45) , and Cit prevented fructose-induced alterations in Arg metabolism, as shown by the normalization of plasma Arg-to-ornithine + Cit and Arg-to-Lys ratios and of plasma Cit, which is a marker of insulin resistance (12, 22) .
In conclusion, both NEAAs and Cit exert beneficial effects on fructose-induced NAFLD. Although the precise mechanisms involved need to be investigated, it seems reasonable to assume that they act via different pathways. Taking into account the influence of AA availability on endoplasmic reticulum homeostasis, we posit that NEAAs may act through GCN2. Cit could act on the liver via PPARa and the down-regulation of SREBP1c, for example, via protein kinase B and mTOR pathway, but also via the improved insulin sensitivity enabled by peripheral Arg bioavailability.
